News Sentiment

ACAD sentiment intelligence

ACADIA Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 26.22 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+1.0% over one week, +24.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.0% Price digesting
Trend fit Trend inactive 24.3% over four weeks
Fair value 23.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 32
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 5
TradingView 5
simplywall.st 5
Moomoo 4
Sahm 3
Simply Wall Street 3
BioSpace 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 19
Analyst action 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Simply Wall Street Direct company coverage

Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome

ACADIA Pharmaceuticals saw its stock rise by 17.1% after the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for DAYBUE (trofinetide) to treat Rett syndrome in the EU. This potential approval would make DAYBUE the first approved therapy for

Tone
Positive 80/100
Event
Regulatory and legal
Published
28 Jun 2026 07:39
Source
Simply Wall Street